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Diabetes affects today an estimated 366 million people world-wide, including 20 million to 40 million of patients with type 1 dia-
betes (T1D). While T1D accounts for 5% to 20% of those with diabetes, it is associated with higher morbidity, mortality and health 
care cost than the more prevalent type 2 diabetes. Patients with T1D require exogenous insulin for survival and should be identi-
fied as soon as possible after diagnosis to avoid high morbidity due to a delay in insulin treatment. It is also important to present 
to the patient correct prognosis that differs by the type of diabetes. From the research point of view, correct classification should 
help to identify the etiologies and to develop specific prevention for T1D. This review summarizes evidence that may be helpful 
in diagnosing T1D in various ethnic groups. Challenges in interpretation of results commonly used to determine the type of dia-
betes are highlighted.
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INTRODUCTION
The current “etiological” classification of diabetes [1] is sum-
marized in Fig. 1. Prior to the 1980s, nearly all children and 
young adults with diabetes were diagnosed with type 1 diabe-
tes (T1D). Today, the proportions have changed, especially in 
Asian and African countries where more youths are diagnosed 
with type 2 diabetes (T2D) than T1D. Among the U.S. children 
10 to 19 years old at diagnosis, half of African-American and 
Hispanic patients and more than half of Asian/Pacific Island-
ers and American Indians have T2D. However, the majority of 
diabetic non-Hispanic white adolescents still have T1D and 
nearly all children with diabetes diagnosed under age ten have 
T1D [2]. 
  With rising obesity rates in children, it is increasingly diffi-
cult to differentiate between T1D and T2D on clinical grounds 
alone. Islet autoantibodies, fasting or stimulated C-peptide lev-
els, and genetic markers provide tools to augment a clinical di-
agnosis. Globally, the incidence of T1D is increasing by up to 
5% per year [3,4], doubling approximately every 20 years [5,6]. 
Over the past 20 years, newly industrialized countries have ex-
perienced an epidemic of T1D, mirroring that of T2D, but like-
ly caused by entirely different environmental agent(s). 
PATHOMECHANISMS OF TYPE 1a 
(AUTOIMMUNE) DIABETES (T1aD)
Diabetes is a heterogeneous group of diseases with the com-
mon feature of hyperglycemia, however, resulting from com-
binations of defects in at least 40 genes and a variety of envi-
ronmental agents. T1aD is caused by lack of insulin due to au-
toimmune destruction of the pancreatic islet beta-cells. The 
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immune system fails to maintain tolerance to beta-cell autoan-
tigens, often in the setting of the HLA-DRB1*03, DQB1*0201, 
DRB1*04, DQB1*0302, and/or the HLA-DRB1*0901, DQB1
*0303 haplotypes. Chronic inflammation in the islets leads, 
usually after years, and rarely in just months or days, to insulin-
dependent diabetes. T1aD is defined by the presence of auto-
antibodies to the beta-cell antigens detected before, at or after 
clinical diagnosis: autoantibodies to insulin (IAA), the tyrosine 
phosphatase insulinoma antigen (IA-2A), glutamic acid decar-
boxylase (GADA), and zinc transporter 8 (ZnT8A). One and 
usually more of these autoantibodies are present in 85% to 95% 
of newly diagnosed T1aD patients, but this proportion varies 
depending on patient’s age, the number and quality of the as-
says used, and ethnicity. A small number of T1aD patients may 
be negative for all islet autoantibodies at diagnosis, despite pres-
ence of the autoantibodies prior or after diagnosis (our own 
observations from the Diabetes Autoimmunity Study in the 
Young [7]).
  The rate of β-cell destruction is quite variable - rapid in 
younger children and those with high risk HLA genotypes, es-
pecially DRB1*03, DQB1*0201, DRB1*04, DQB1*0302, and 
slower in adolescents and adults and those with lower-risk 
HLA genotypes. This may explain a higher proportion of slow-
ly progressing T1D reported in Asian and African populations 
where a larger proportion of the patients carry neutral or pro-
tective HLA-DR, DQ genotypes. In Japan, ~10% of children 
with diabetes are diagnosed with “slowly progressing T1D.” 
Most are picked on a school-children screening for glucosuria. 
While their progression to full insulin dependence is slower, 
90% have islet autoantibodies or HLA genotypes consistent with 
classical T1aD (Nan Tajima, personal communication, 2010).
  Some patients, particularly children and adolescents, may 
present with ketoacidosis as the first manifestation of the dis-
ease. Others have modest hyperglycemia that can rapidly de-
compensate in the presence of infection or other stress. Still 
others, particularly adults, may retain residual β-cell function 
sufficient to prevent ketoacidosis for many years; such individ-
uals eventually also become dependent on insulin for survival 
and are at risk for ketoacidosis. At this latter stage of the disease, 
there is little or no insulin secretion, as manifested by low or 
undetectable levels of plasma C-peptide. Immune-mediated 
diabetes commonly occurs in childhood and adolescence, but 
it can occur at any age, even in the 8th and 9th decades of life. 
In Western countries, more than half of T1D patients are diag-
nosed after the age of 20 years.
MONOGENIC AUTOIMMUNE 
POLYENDOCRINE SYNDROMES (APS)
APS1 is a rare syndrome caused by a truncation of the autoim-
mune regulator gene (AIRE). The syndrome is defined by the 
combination of Addison’s disease, hypoparathyroidism, and 
mucocutanous candidiasis; oophoritis is quite common. T1aD 
is present in ~20% of the cases. 
  Immunodeficiency, polyendocrinopathy, enteropathy, X-
linked (IPEX) syndrome is caused by one of several possible 
mutations in the FOXP3 gene [8] on the X chromosome. Only 
males are affected. The patients develop chronic enteropathy, 
eczema, autoimmune thyroid disease, anemia, and T1aD (in 
about 60% of the cases).
PATHOMECHANISMS OF TYPE 1b 
(IDIOPATHIC) DIABETES (T1bD)
Some forms of type 1 diabetes demonstrate permanent insu-
linopenia and proneness to ketoacidosis, but no evidence of 
autoimmunity. Only a small proportion of T1D patients fall 
into this category, of those who do, most are of African or Asian 
ancestry.
FULMINANT T1bD
Fulminant type 1 diabetes was first described by Japanese in-











Typical (HLA-DR3, 4 or 9)  Fulminant  HNF4A  KCNJ11
Slow progressing    GCK  ABCC8               
LADA  “African”  HNF1A, 1B  INS
APS1, IPEX    PDX1  PTF1A
      NeuroD1  EIF2AK3
              ~5-20% of all diabetes    
MODY PNDM
Polygenic
Type 2 Type 1a Type 1b
Fig. 1.  Current classification of diabetes. APS1, autoimmune 
polyendocrine syndromes 1; IPEX, immunodeficiency, poly-
endocrinopathy, enteropathy, X-linked syndrome; MODY, 
maturity-onset diabetes of the young. 92
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Chinese [14], French [15], and the U.S. Hispanic patients [16]. 
Typical features of this syndrome include: severe hyperglyce-
mia and DKA shortly after the onset of diabetic symptoms and 
normal HbA1c levels. A rapid and almost complete destruction 
of beta cells leads to low C-peptide levels, no remission period, 
and a complete insulin dependency. High frequency of flu-like 
symptoms has been reported as well as elevated pancreatic en-
zymes, pointing perhaps to a primary infection of the exocrine 
pancreatic tissue. Pregnant women appear to be disproportion-
ally affected. While fulminant diabetes is believed to be distinct 
from typical T1aD, insofar that chronic islet autoimmunity 
contributes less critically to the beta-cell damage than a hy-
pothesized viral infection, there appears to be a significant 
overlap between these two types of diabetes in their HLA-DR, 
DQ associations and the presence of insulitis with beta-cell 
antigen-reactive T-cells. Interestingly HLA-identical dizygotic 
twins have been reported, one with typical T1aD and the other 
with fulminant diabetes [17] diagnosed at different times. While 
GADA was reportedly “infrequent” (<5%) and IA-2A absent, 
none of the studies so far have measured IAA or ZnT8 levels. It 
appears that this syndrome perhaps represents an extreme end 
of the T1aD spectrum, rather than an etiologically distinct dis-
ease. The syndrome remains rare, affecting <1% of children 
with diabetes in Japan (Nana Tajima, personal communication, 
2010).
KETOSIS-PRONE T1bD
Several reports from sub-Saharan Africa [18-21] and the U.S. 
African-American population [22-25] have described atypical 
ketosis-prone “African” diabetes. While this clinical entity re-
mains poorly defined, the common characteristics appear to 
include acute onset, often with ketoacidosis, in often obese ad-
olescents or young adults with no islet autoantibodies and HLA 
genotypes inconsistent with T1aD. The post-diagnosis course 
is characterized by nearly complete remissions followed by slow 
progression to insulin dependence with periods of normogly-
cemia intertwined with episodes of hyperglycemia and ketosis 
requiring insulin. Strong family history of diabetes and male 
predominance has been reported, while age at onset and body 
mass index (BMI) have varied across studies. Preliminary data 
from nPOD [26] showed no pseudoatrophic islets characteris-
tic to T1aD, confirming clinical observations of C-peptide lev-
els preserved many years after diagnosis. While some believe 
that in Africa ketosis prone T1bD is more frequent than the 
classical T1aD, more of untreated T1aD than T1bD patients 
may be dying prior to or shortly after diagnosis.
CHALLENGES IN THE INTERPRETATION OF 
TESTS USED TO DIAGNOSE T1D
The clinical and laboratory characteristics used currently to 
distinguish T1D and especially T1aD are summarized in Table 
1. Their advantages and limitations are reviewed below. 
Islet autoantibodies 
Autoantibodies to biochemically characterized beta-cell auto-
antigens: IAA, IA-2A, GADA, and ZnT8A [27] help to define 
T1a, if measured prior to or shortly after initiation of insulin 
therapy. IAA are masked by antibodies induced by exogenous 
insulin and become very hard to measure after just 10 to 14 
days of insulin therapy. ZnT8A tend to disappear quickly after 
diagnosis of diabetes, while GADA and IA-2A tend to persist 
longer, but are rarely seen more than 5 years after diagnosis. 
Testing for at least two of these autoantibodies at diagnosis is 
now considered standard of care in T1D. Good commercial 
assays exist for IA-2A, GADA, and ZnT8A, with the former 
two recently harmonized [28]. IAA are low-affinity antibodies 
and harder to measure; however, high-quality non-radioactive 
assays for IAA are close to being commercially available [29]. 
The search for additional islet autoantibodies and assay that 
would reliably detect autoreactive T-lymphocytes are active 
areas of research.
  The prevalence of antibodies in patients with T1D varies 
depending on the study population and methods of antibody 
assessment. In the multi-center SEARCH trial of newly diag-
nosed cases of T1D and T2D in youth 0- to 19-year-old, 52% 
were positive for GADA, 60% were positive for IA-2A and 38% 
were positive for both [30]. This study did not test for IAA or 
ZnT8A and obtained the blood sample months to years after 
diagnosis. In contrast, the Childhood Diabetes in Finland Study 
Group found that among newly diagnosed children with T1D, 
91% tested positive for at least two antibodies and 71% for three 
or more. Further, IA-2A was detected in 86% of cases [31].
  We recommend that as many biochemical islet autoantibody 
assays as possible (up to 4) are used while confirming the di-
agnosis of T1aD. If only GADA and IA-2A are measured - up 
to 20% of truly T1aD patients will be missed as they have only 
IAA or ZnT8A; the latter should be measured immediately at 
diagnosis. Positivity for one of the autoantibodies usually suf-93
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fice; positivity for 2 or more removes any doubt concerning 
diagnosis of T1aD (see below).
  Islet autoantibodies can by falsely positive as often as patients 
with T2D as in non-diabetic persons. Let us consider that a 
clinician is using one assay, e.g., GADA, that is 95% specific for 
T1aD. In a mixed patient population of 300 T2D subjects and 
30 T1aD patients, 35% of positive GADA results will be false-
positive. However, using a better assay, with a 99% specificity, 
would result in only 10% of false-positive results.
  The likelihood of obtaining false-positive results increases 
with application of multiple assays. Table 2 illustrates results of 
testing of the same mixed population of patients with T2D and 
T1aD using four islet autoantibody assays, each characterized 
by 60% sensitivity and 99% specificity. Bayesian probability of 
a false-positive finding in T2D patients is 12/300 (4%), howev-
er, none of the T2D patients would be expected to be positive 
for more than one autoantibody. The same probabilities of false-
positive findings would apply to 300 non-diabetic subjects 
screened for islet autoantibodies. Please note that even with 
four excellent assays, one (3.3%) of the 30 T1aD patients is ex-
pected to be negative for all autoantibodies and only 4 would 
be positive for all four. 
  Two groups have reported development of islet autoanti-
bodies in ~10% of initially negative MODY3 patients [32] and 
~40% of patients with permanent neonatal diabetes due to a 
KCNJ11 gene mutation [33]. This appears to usually happen 
many years after diagnosis and awaits biological explanation.
 
C-peptide levels
Nearly half of adults with T1aD have significant C-peptide lev-
els within 5 years of diagnosis, and 8% had significant C-pep-
tide 5 to 15 years after diagnosis [34]. The rate of C-peptide 
disappearance in T1aD patients diagnosed in their 30’s is ~20% 
Table 1.  Practical phenotypic features to differentiate between type 1 and type 2 diabetes
  Type 1 diabetes (T1D) Type 2 diabetes (T2D)
Islet autoantibodies Present in ~100% of T1aD cases False-positive results not uncommon  
Can develop in MODY patients
C-peptide   Initially can be normal or low; disappears usually in 2 to 5 
years
Initially high or normal; usually persists for years
Genotyping HLA-DRB1*03, DQB1*0201, or DRB1*04, DQB1*0302, or 
DRB1*0901, DQB1*0303 present in >90% of T1aD
Not clinically useful, except for monogenic forms 
of diabetes
Family history 5% to 15% of the first degree relatives may have T1D >50% of the first degree relatives may have T2D
Obesity Not a reliable exclusion criterion Usually present at some point, but no always at di-
agnosis of diabetes
Insulin sensitivity Can be normal, usually low  Usually very low
Presence of other autoim-
mune disease
In ≥20% of T1aD (>50% of the patients have other autoant-
bodies)
As expected in the general population
Age of onset Diagnosed in 50% cases during  childhood, 50% in adults; 
99% of diabetic children <10 yr
Diagnosed in >95% of cases in adults;  
10-15% of diabetic teens
DKA at onset 20-40%; higher in populations where T1D is rare <10%
Insulin dependence Complete in typical cases 
Sometimes developing slowly
Initially absent in most cases
T1aD, type 1a (autoimmune) diabetes.
Table 2.  Bayesian probabilities of a positive autoantibody test 





Type 2 diabetes, No. 
(n=300)
Type 1 diabetes, No. 
(n=30)
Autoantibody  Autoantibody 
Positive Negative Positive Negative
1 12 288 29 1
2 0 300 25 5
3 0 300 14 16
4 0 300 4 26
Four independent assays used (IAA, GADA, IA-2A, and ZnT8), each 
had specificity 99%, sensitivity 60%.
T1aD, type 1a (autoimmune) diabetes; T2D, type 2 diabetes; IAA, au-
toantibodies to insulin; GADA, glutamic acid decarboxylase; IA-2A, 
the tyrosine phosphatase insulinoma antigen; ZnT8A, zinc transport-
er 8.94
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to 30% per year, slower than that among teenagers (45% to 55% 
per year) or younger children (60% to 90% per year). Thus 
persistence of beta-cell function is rare in young children with 
T1aD, especially those with the highest-risk HLA-DR, DQ 
genotypes and multiple islet autoantibodies. While measure-
ment of C-peptide levels post stimulation with mixed meal or 
intravenous glucagon remains the gold standard for clinical 
trials, fasting C-peptide levels are more readily available in 
clinical practice for differential diagnosis of T1D vs. T2D. The 
5th and 50th percentiles of fasting C-peptide in healthy ado-
lescents, aged 12 to 19 years, who participated in the National 
Health and Nutrition Survey 1999 to 2002 were, respectively, 
1.0 and 1.9 ng/mL [35] while the levels ≥0.23 ng/mL are con-
sidered clinically helpful in lowering the risk of long-term com-
plications (J. Lachin, P.F. McGee, DCCT, unpublished data). 
The SEARCH study has demonstrated [36] that the current 
classification defining T1D as a state of absolute insulin defi-
ciency and T2D as a state of insulin resistance combined with 
inadequate insulin secretion (Fig. 1) is inadequate. During the 
1st year after diagnosis, almost one-third of children with T1aD 
had C-peptide values that exceeded the 5th percentile and 7% 
exceeded the 50th percentile for healthy adolescents [36]. Thus, 
health care providers should be careful not to use normal C-
peptide levels as a guide to delay insulin treatment in patients 
with the T1aD phenotype. Practically speaking, while absent 
or low C-peptide confirms diagnosis of T1D in islet autoanti-
body negative patients, normal C-peptide levels are expected 
in either T1D or T2D patients.
Genetic markers 
Individuals with the HLA-DRB1*03, DQB1*0201/DRB1*04,
DQB1*0302 genotype are at approximately 20-fold increased 
risk for T1aD compared to the general population. This high 
risk genotype is present in 2.4% of newborns of European an-
cestry [37], but less frequent in Africans or Asians [38]. By age 
15, 5% of children with this genotype will develop islet auto-
immunity and T1D, compared with only 0.3% in the general 
population. A number of additional HLA class II genotypes 
confer moderately increased risk for T1D, while others are 
protective.
  Non-HLA associated loci that result in increased risk of T1D 
include those that influence immunity (INS, PTPN22, IL2RA, 
SH2B3), insulin production and metabolism (ERBB3), and 
many others. A number of novel loci identified through ge-
nome-wide association studies have been confirmed in pro-
spective population-based studies. However, jointly they con-
fer only a small additional risk compared to the effect of HLA-
DR and DQ. An up-to-date review of all genes implicated in 
the development of T1D can be found at T1Dbase (http://
www.t1dbase.org). 
  In practice, genotyping is rarely used to distinguish T1aD 
from other forms of diabetes. However, HLA-DR, DQ typing 
is worth of consideration in autoantibody negative cases where 
other factors, e.g., clinical course, family history or presence of 
other autoimmune diseases suggest T1aD. Among islet auto-
antibody negative diabetic patients younger than 20, at the Bar-
bara Davis Center in Colorado, 32% of non-Hispanic whites 
had HLA-DR, DQ genotypes compatible with T1aD, compared 
to only 13% Hispanic, and 5% African American patients. More 
work is needed to fully utilize genetic markers, especially in 
non-European ethnic groups. Non-HLA class II markers are 
likely of little value, except for highly specific AIRE or FOXP3 
mutations, if clinical picture suggests the APS1 or IPEX, re-
spectively.
Family history of T1aD 
At the time of diagnosis, over 85% to 95% of patients with T1D 
lack a family history of the disease in immediate relatives. This 
proportion decreases over time, as by the time the patients 
reaches age 40, in about 10% of the families a sibling, parent or 
offspring develops T1D [39,40]. Thus, while T1D among first-
degree relatives of a patient strongly suggest diagnosis of T1D, 
negative family history does not help to rule it out.
Obesity
The presence of obesity is compatible with diagnosis of T1aD. 
In fact, about half of the patients with BMI ≥27 diagnosed with 
diabetes before the age of 20 in the U.S. had T1aD (Fig. 2). 
Insulin sensitivity
Several lines of evidence support the hypothesis that insulin 
resistance may accelerate progression to over hypoglycemia 
among persons with islet autoimmunity and significant beta-
cell defect, however, the independent effect of insulin resis-
tance on progression to T1aD appeared to be modest [41]. The 
SEARCH study in the U.S. attempted to classify cases of child-
hood diabetes using the presence of GADA and/or IA-2A as 
well as insulin sensitivity estimated from the patient’s waist 
circumference, HbA1c and triglyceride levels [30]. Not unex-
pectedly, children who were positive for islet autoantibodies 95
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were similar genetically, in terms of their C-peptide levels, 
presence of DKA or clinical course post diagnosis regardless 
of being classified as “insulin resistant” or “insulin sensitive.” 
Insulin sensitivity is a fleeting phenotype that may changes 
within weeks, even days, with changes in physical activity, diet 
composition, body weight, and hyperglycemia levels. Most 
T1aD patients are insulin resistant compared to BMI-age-
matched non-diabetic controls [42]. In addition, indices of in-
sulin sensitivity derived from clinical variables correlate poor-
ly with insulin sensitivity levels measured directly using eugly-
cemic hyperinsulinemic clamp. Therefore, assessment of insu-
lin sensitivity, even using invasive methods, is unlikely to be of 
help in ruling out T1D.
Presence of other autoimmune diseases
Due to shared genetic susceptibility, T1aD often coexists with 
autoimmune disorders such as celiac disease, Hashimoto’s thy-
roiditis, Graves’ disease Addison’s disease, vitiligo, autoimmune 
hepatitis, myasthenia gravis, and pernicious anemia. Presence 
of any of these conditions or serologic evidence of subclinical 
autoimmunity, e.g., autoantibodies against tissue transgluta-
minase, thyroid peroxidase, 21-hydroxylase or parietal cells, 
may aid correct classification in borderline cases.
CONCLUSIONS 
With increasing rates of obesity, it is becoming increasingly 
difficult to distinguish between T1D and T2D. In absence of 
islet autoantibodies, it may take weeks or months of observa-
tion to accurately diagnose a child with features of both T1D 
and T2D. It must be noted that for a child presenting with sus-
tained hyperglycemia or DKA, insulin therapy must precede 
definitive laboratory results, even in ambiguous cases. Fig. 3 
summarizes our experience in classifying diabetes into T1a, 
T1b, and T2 in the multiethnic population of patients diag-
nosed below age 20, in Colorado, the USA.
  The scheme is based primarily on islet autoantibody testing, 
with the aid of HLA-DR, DQ genotyping and fasting C-peptide 
measurement in autoantibody negative subjects. While the ge-
netic markers used will need to be customized for other ethnic 
groups, especially of Asian or African origin, this scheme is 
likely to minimize expense and maximize accuracy of assign-
ing the correct type of diabetes in different populations.
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